Sai Parenteral IPO 2026 | Should You Invest?

While the broader pharmaceutical narrative is shifting towards innovation, specialty drugs, and biologics, the global healthcare system continues to depend heavily on scalable, cost-efficient manufacturing of generics and formulations.

At the same time, increasing regulatory complexity and cost pressures are pushing pharma companies to outsource development and manufacturing.

This is where Sai Parenteral’s has built its business, combining formulation manufacturing with a growing focus on CDMO services and export markets.

Now the company is coming to the market with its ₹409 crore issue at a price band of ₹372-₹392, combining a ₹285 crore fresh issue and ₹124 crore OFS.

The investment case, therefore, is not just about a pharma manufacturer coming to market, but about whether a mid-sized player transitioning toward a CDMO-led, export-driven model can carve out a sustainable position in an increasingly competitive industry.

Let’s unpeel the layers now!

The company operates across two core verticals:

• Branded Generic Formulations
• Contract Development and Manufacturing Organisation (CDMO)
   

The formulations business forms the foundation of operations. Sai manufactures and supplies a wide range of products including injectables, intravenous fluids, oral solids, and nutraceuticals, catering to domestic institutions such as government agencies, hospitals, and pharmaceutical distributors

Within this, sterile injectables are a key segment, requiring higher regulatory compliance and offering better margins compared to standard oral formulations.

This segment remains operationally dominant and financially central, anchoring the company’s current revenue base.

Alongside this, Sai Parenteral’s has been expanding its CDMO business, offering end-to-end services such as: product development, stability studies, regulatory filings and commercial manufacturing.

 
This vertical is strategically important as it allows the company to move up the value chain and participate in global pharmaceutical outsourcing trends.

The company’s export business is relatively recent but increasingly important. Exports began meaningfully only after FY23, following the acquisition of internationally compliant manufacturing units.

Today, Sai exports to regulated and semi-regulated markets including Australia, New Zealand, Southeast Asia, the Middle East, and Africa

A key driver of this expansion is the acquisition of Noumed Pharmaceuticals, which provides:

• Access to regulated market distribution (Australia & New Zealand)
• A portfolio of 450+ dossiers
• Established relationships with pharmacy chains and institutional buyers
   

This significantly strengthens its positioning as a CDMO and export-focused player, rather than just a domestic formulation company.

Here are the key details investors should know:

• IPO Size: ~₹409 crore
• Fresh Issue: ~₹285 crore
• Offer for Sale (OFS): ~₹124 crore
• Price Band: ₹372 – ₹392 per share
• IPO Dates: 24 – 27 March 2026
• IPO Type: Fresh Issue + Offer for Sale (OFS)
• Minimum Investment: ₹14,136 (38 shares – lot size)
• Listing Date: 2 April 2026
• Proposed Listing: BSE & NSE
• Lead Manager: Arihant Capital Markets Ltd

Sai Parenteral’s IPO is also a mix of fresh issue and Offer for Sale (OFS), which means the proceeds are split between the company and existing shareholders.

Out of the total issue size of ~₹409 crore, around ₹285 crore is a fresh issue, while ~₹124 crore is an OFS.

The fresh issue portion will go to the company, and is earmarked for specific business needs, including:

This indicates a mix of growth (capex + R&D) and balance sheet strengthening (debt repayment).

On the other hand, the ~₹124 crore OFS will go entirely to the selling shareholders, and will not be received by the company.

Sai Parenteral’s financial performance reflects a business that is scaling rapidly, improving profitability, and benefiting from operating leverage, but still remains largely driven by its core formulation segment while newer verticals like CDMO and exports are in the build-out phase.

Revenue from operations has shown a strong upward trajectory over the last few years. It stood at ₹968 crore in FY23, increased sharply to ₹1,538 crore in FY24, and further to ₹1,631 crore in FY25. In H1 FY26 alone, the company has reported ₹869 crore, indicating continued growth momentum heading into the current year.

The sharp jump between FY23 and FY24 is particularly notable, and appears to be driven by a combination of capacity additions, acquisitions, and initial export ramp-up, rather than purely organic growth. FY25 growth, while positive, is relatively moderate, suggesting a phase of consolidation after expansion.

At the EBITDA level, margins have expanded meaningfully from 18.2% in FY23 to 20.6% in FY24 and further to 24.2% in FY25, before moderating slightly to 18.7% in H1 FY26. At the PAT level, margins have shown a steady and consistent improvement. They have increased from 4.5% in FY23 to 5.5% in FY24 and further to 8.9% in FY25, sustaining at around 9.0% in H1 FY26. This suggests that profit conversion has improved as the business scaled, although margins are still below those of pure-play CDMO peers, reinforcing the fact that the business is still in transition.

Return ratios reflect this improvement in efficiency. ROCE has improved to 28.9% in FY25, indicating that the capital deployed during the expansion phase is beginning to generate returns.

On the balance sheet side, leverage has increased in recent years, largely due to acquisitions and capacity expansion. Total borrowings rose from ₹685 crore in FY23 to ₹1,188 crore in FY24, before moderating to ₹940 crore in FY25.

At the upper price band of ₹392, the IPO is valued at approximately 72.2× P/E, 3.5× P/B, 10.6× P/S, and 45.5× EV/EBITDA.

In comparison, Sai Life Sciences, a more CDMO-focused player, trades at ~107.7× P/E and ~40.7× EV/EBITDA, reflecting its stronger positioning in high-value outsourcing and regulated markets. On the other hand, Innova Captab trades at a much lower ~32.5× P/E and ~22.4× EV/EBITDA, given its more formulation-heavy and domestic-oriented business model.

Senores Pharmaceuticals, with a mix of formulations and exports, trades at ~64.3× P/E and ~33.8× EV/EBITDA, while Gland Pharma, a well-established injectable player with strong global presence, trades at ~44.7× P/E and ~19.5× EV/EBITDA.

Relative to the broader industry average of ~62.3× P/E and ~29.1× EV/EBITDA, Sai Parenteral’s is priced at a premium on EV/EBITDA and P/S, while being broadly in line to slightly higher on P/E.

On P/B, the company trades at ~3.5×, which is lower than Sai Life Sciences (~8.6×) and broadly comparable to Gland Pharma (~3.4×), suggesting that the valuation is not excessive on a balance sheet basis.

However, this valuation needs to be viewed in context. Sai Parenteral’s is still transitioning from a formulation-led business to a CDMO and export-oriented platform, whereas peers like Sai Life Sciences and Gland Pharma already have established positioning in regulated markets and higher-value segments.

The relatively elevated EV/EBITDA multiple of ~45× indicates that the market is already factoring in future growth, margin expansion, and successful scaling of CDMO operations. At the same time, the company remains smaller in scale and earlier in its transition cycle compared to several listed peers.
 

• Customer Concentration Risk: A large portion of revenue comes from a limited set of customers. In formulations, the top 5 customers contributed over ~70% across recent periods. This creates dependency on a few buyers, where loss of a key customer or pricing pressure can directly impact revenue and margins.
• Regulatory and Compliance Risk: Pharma manufacturing is heavily regulated, especially for export markets. Sai’s facilities undergo frequent inspections, and any adverse observation, warning letter, or license issue can disrupt production, exports, and customer relationships.
• Raw Material and Supplier Dependency: The company relies on third-party suppliers for APIs and key inputs without long-term contracts. This exposes it to supply disruptions, quality issues, and cost volatility, with limited control over input pricing.
• Working Capital Intensity: The business operates with high receivables and inventory, typical of institutional and export pharma. Delays in collections or higher credit periods can strain cash flows, even if profits grow.
• Business Mix Transition Risk: Sai is positioning itself as a CDMO and export-driven company, but revenues are still largely formulation-led. If CDMO scaling or export ramp-up is slower than expected, the valuation narrative may not fully play out.
• Product Development Risk: Future growth depends on successful commercialisation of new products and dossiers. Delays in approvals or weak market uptake can reduce returns on R&D investments. 
• Overseas Expansion & Noumed Integration: The Noumed acquisition is central to the export strategy. Any integration issues, underperformance, or regulatory challenges in overseas markets can affect growth expectations.
• Leverage and Balance Sheet Risk: Borrowings increased during the expansion phase, and part of the IPO is being used to repay debt. This indicates that growth has been capital-intensive and partly debt-funded.
• Geographic Concentration of Facilities: Most manufacturing units are located in and around Hyderabad. Any regional disruption could impact multiple facilities simultaneously.
• Export and Currency Risk: Increasing international exposure brings risks related to foreign exchange fluctuations, regulatory differences, and market-specific challenges.

Sai Parenteral’s operates at the intersection of formulation manufacturing and CDMO services, with a business that is still largely formulation-led but gradually expanding into exports and higher-value outsourcing opportunities.

At the upper price band of ₹392, the IPO is valued at approximately 72.2× P/E, broadly in line to slightly above the industry average of ~62×, while the EV/EBITDA of ~45.5× is at a clear premium to most listed peers.

This premium suggests that the market is already factoring in future growth, margin expansion, and successful execution of the CDMO and export strategy, rather than just current earnings.

However, this valuation needs to be seen in context. Sai Parenteral’s is still earlier in its transition cycle, with a smaller scale and evolving business mix compared to more established CDMO and injectable players. In addition, factors such as working capital intensity, regulatory dependency, and acquisition-led growth introduce execution risk.

In that sense, the IPO is not positioned as a value opportunity, but rather as a growth-led story, where returns will depend on how effectively the company can transition from a formulation-heavy domestic player to a more diversified, export-oriented CDMO platform.

1. What are the IPO dates for Sai Parenteral’s IPO?
The IPO of Sai Parenteral’s Limited opens on March 24, 2026 and closes on March 27, 2026. The shares are proposed to be listed on April 2, 2026 on the BSE and NSE.

2. What is Sai Parenteral’s IPO GMP?
Grey market activity indicates market interest in the IPO. Check the live GMP for the Sai Parenteral IPO here. (GMPs are unofficial and can change rapidly.)

3. What is the lot size for retail investors?
The minimum lot size is 38 shares, which translates to a minimum investment of approximately ₹14,136-₹14,896 at the price band.

4. Is the Sai Parenteral’s IPO a fresh issue or an OFS?
The IPO is a combination of a Fresh Issue and an Offer for Sale (OFS). The fresh issue proceeds will go to the company for expansion, R&D, debt repayment, and working capital. The OFS portion will go to existing shareholders.

5. Should I invest in Sai Parenteral’s IPO?
Investors looking for exposure to the pharmaceutical manufacturing and CDMO segment may find the IPO interesting. However, they should carefully consider risks such as regulatory dependency, working capital intensity, and execution of the export/CDMO strategy before investing.